Home > About LGC > Financial results > 2005-06 results

About LGC

Financial results

 

Financial highlights 2005-2006

These are the tenth results since LGC was privatised in 1996 which, taken collectively, demonstrate consistent international growth in the UK, Europe and in India in the past 10 years.

International growth

LGC's growth internationally was marked this year by the opening of our first laboratory in India and through two acquisitions in Germany. In LGC's largest acquisition to date, growth in the UK progressed through the acquisition of Forensic Alliance Limited (FAL) in August 2005. During the year, all areas of the business have grown organically and contributed to another record annual turnover of £85.9m.

Highlights of the past year include:

  • Launching LGC Forensics (following the acquisition of FAL) to provide customers in the Criminal Justice System with a fully comprehensive forensic resource from six sites: Teddington, Culham (near Oxford), Tamworth, Risley, Runcorn and a specialist firearms facility in conjunction with the Royal Armouries in Leeds.
  • Bringing together our products and services for laboratory quality into a single international division comprising LGC Promochem, LGC's proficiency testing interests with newly acquired subsidiaries QM and Aquacheck, and our laboratories in Luckenwalde, Germany and Bangalore in India to synthesise pharmaceutical impurities;
  • LGC's first European patent grant for its HyBeacons® rapid DNA probe technology, with a second patent pending;
  • In Germany, the specialist genomics company, AGOWA, based in Berlin, joining the LGC Group and building on our life science, DNA and high throughput operations and, with the acquisition of the Institut für Blutgruppenforschung based in Köln, entering the German paternity testing and forensic genetics market;
  • Becoming the first independent accredited laboratory to be approved as a member of the Department of Health's UK Genetic Testing Network (UKGTN);
  • In an exclusive agreement with King's College London, offering the first pharmacogenetic screening service to predict whether a patient with schizophrenia will respond positively to the antipsychotic drug clozapine;
  • Reflecting the replacement of the OTM Rule in November 2005 in our BSE testing operations for Defra to provide an overnight service to abattoirs licensed to process OTM cattle for human consumption;
  • Winning the Department of Health contract for the National Institute for Health Research in which LGC operates the Central Commissioning Facility with TUV NEL Ltd, and provides R&D programme management.

 

Annual Review 2006 (4.04 MB)

Report and Accounts 2006 (698KB)